Clinical Trials/JPRN-UMIN000030909

JPRN-UMIN000030909

Recruiting

Phase 1

Phase I/II trial of combined chemotherapy of Nab-paclitaxel, S-1, and Oxaliplatin for gastric cancer patients with peritoneal metastasis (NSOX study) - NSOX study

Wakayama Medical University, School of Medicine0 sites35 target enrollmentJanuary 20, 2018

Conditionsgastric cancer with peritoneal metastasis

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: gastric cancer with peritoneal metastasis
Sponsor: Wakayama Medical University, School of Medicine
Enrollment: 35
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

January 20, 2018

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Wakayama Medical University, School of Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\. History of hypersensitivity to nab\-paclitaxel, S\-1, oxaliplatin 2\. Contraindication to nab\-paclitaxel, S\-1, oxaliplatin 3\. Infectious disease 4\. HBs\-antigen positive 5\. Severe complication 6\. Neuropathy with symptoms 7\. Brain metastasis with clinical symptoms 8\. Watery diarrhea. 9\. Active double cancer 10\. Persons to be pregnant or to make pregnant 11\. Any subject judged by the investigator to be unfit for any reason to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Phase I study of combination chemotherapy with nab-paclitaxel and Nedaplatin as first-line treatment in patients with advanced squamous cell lung cancer.Squamous cell lung cancer

JPRN-UMIN000010963Kitasato University School of Medicine Department of Respiratory Medicine16

Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer.cervical cancer

JPRN-UMIN000024137Hyogo Cancer Center30

Phase I/II trial of combination chemotherapy using TS-1, CPT-11 and cetuximab with radiation in locally advanced rectal cancerRectal cancer

JPRN-UMIN000002602Yokohama City University Graduate School of Medicine35

Phase I-II study of combination chemotherapy with Irinotecan and Gemcitabine for clear cell or mucinous ovarian cancerClear cell or mucinous ovarian cancer

JPRN-UMIN000005952Osaka university, faculty of medicine40

Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.

JPRN-UMIN000009362ational Cancer Center Hospital, Tokyo, Japan.12